Relmada Therapeutics Investor Presentation — June 2021

Document content

Advances in Treatment

June 2021 I Nasdaq: RLMD

Certain statements contained in this presentation or in other documents of Relmada Therapeutics, Inc. (the “Company”), along with

certain statements that may be made by management of the Company orally in presenting this material, may contain “forward -lookin g

statements.” These statements can be identified by the fact that they do not relate strictly to historic or current facts. Th ey use words

such as “estimate,” “expect,” “intend,” “believe,” “plan,” “anticipate,” “projected” and other words and terms of similar mea ning in

connection with any discussion of future operating or financial performance or condition. These statements are based upon the current

beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties. Statements regar ding

future action, future performance and/or future results including, without limitation, the proposed offering, those relating to the timing

for completion, and results of, scheduled or additional clinical trials and the FDA’s or other regulatory review and/or appro valand

commercial launch and sales results (if any) of the Company’s formulations and products and regulatory filings related to the same

may differ from those set forth in the forward -looking statements. Peak sales and market size estimates have been determined on the

basis of market research and comparable product analysis, but no assurances can be given that such sales levels will be achie ved,

if at all, or that such market size estimates will prove accurate.

Because actual results are affected by these and other potential risks, contingencies and uncertainties, the Company cautions

investors that actual results may differ materially from those expressed or implied in any forward -looking statement. It is not possible

to predict or identify all such risks, contingencies and uncertainties. The Company identifies some of these factors in its S ecurities

and Exchange Commission (“SEC”) filings on Forms 10 -K, 10 -Q and 8 -K, and investors are advised to consult the Company’s filings

for a more complete listing of risk factors, contingencies and uncertainties affecting the Company and its business and finan cial

The Company assumes no obligation to update forward -looking statements as circumstances change. Investors are advised to consult

further disclosures that the Company makes or has made on related subjects in the Company’s Form 10 -K, 10 -Q and 8 -K reports.

2Investment Highlights

De-risked Lead Product

Key Catalysts Expected

Over Next 3 -18 Months